Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern | EMBO reports
Rapid characterization of spike variants via mammalian cell surface display
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments | ACS Applied Bio Materials
Frontiers | The Mechanism of Lung and Intestinal Injury in Acute Pancreatitis: A Review
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface | Nature Communications
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2 - eBioMedicine
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants | Nature Communications
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes | Nature Communications
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion | Nature
Rapid characterization of spike variants via mammalian cell surface display - ScienceDirect
Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review - K - 2022 - Journal of Medical Virology - Wiley Online Library
新型コロナウイルス感染症に関する 国内外の研究開発動向について
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma - Wang - 2020 - Cancer Medicine - Wiley Online Library
新型コロナウイルス感染症に関する 国内外の研究開発動向について
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe
Rapid characterization of spike variants via mammalian cell surface display | bioRxiv
ACWI ex JAPAN ex CHINA A 2022 May SAIR Constituent
新型コロナウイルス感染症に関する 国内外の研究開発動向について
Easy & Reliable – Biomedica´s Cytokine ELISA Kits | Biomedica
Frontiers | Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern | EMBO reports
新型コロナウイルス感染症に関する 国内外の研究開発動向について
Monoclonal antibody therapies against SARS-CoV-2 - The Lancet Infectious Diseases
Guideline Therapeutics and COVID-19: living guideline
